UroGen Pharma Ltd. (URGN) financial statements (2021 and earlier)

Company profile

Business Address 9 HA'TA'ASIYA ST
RA'ANANA, 4365007
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments102147101
Cash and cash equivalents5350101
Short-term investments4997 
Restricted cash and investments110
Receivables7  
Inventory, net of allowances, customer advances and progress billings2  
Inventory2  
Other undisclosed current assets311
Total current assets:116149102
Noncurrent Assets
Operating lease, right-of-use asset24
Property, plant and equipment211
Long-term investments and receivables249 
Long-term investments249 
Restricted cash and investments000
Other noncurrent assets000
Total noncurrent assets:6541
TOTAL ASSETS:122202104
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:10119
Accounts payable354
Accrued liabilities112
Other undisclosed accounts payable and accrued liabilities662
Debt 2 
Other liabilities22 
Other undisclosed current liabilities1055
Total current liabilities:211913
Noncurrent Liabilities
Long-term debt and lease obligation13 
Operating lease, liability13
Liabilities, other than long-term debt3  
Liability for uncertainty in income taxes3  
Total noncurrent liabilities:43 
Total liabilities:262213
Stockholders' equity
Stockholders' equity attributable to parent9618090
Common stock000
Additional paid in capital453408213
Accumulated other comprehensive income00 
Accumulated deficit(357)(228)(123)
Total stockholders' equity:9618090
TOTAL LIABILITIES AND EQUITY:122202104

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Revenues1201
Sublease income00
Cost of revenue(1) (2)
Other undisclosed gross profit (0) 
Gross profit:110(1)
Operating expenses(138)(109)(77)
Operating loss:(127)(109)(77)
Nonoperating income (expense)2(0) 
Investment income, nonoperating2  
Other nonoperating expense (0) 
Other undisclosed loss from continuing operations before equity method investments, income taxes(0)  
Loss from continuing operations before equity method investments, income taxes:(125)(110)(77)
Other undisclosed income from continuing operations before income taxes 52
Loss from continuing operations before income taxes:(125)(105)(76)
Income tax expense(3) (0)
Net loss available to common stockholders, diluted:(128)(105)(76)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Net loss:(128)(105)(76)
Other comprehensive income (loss)(0)0 
Comprehensive loss, net of tax, attributable to parent:(128)(105)(76)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: